Wang Xuemei, Yu Shun, Li Fangfei, Feng Tao
Center for Neurodegenerative Disease, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, #6 Tian Tan Xi Li Street, 100050 Beijing, China.
Department of Neurobiology, Xuanwu Hospital, Capital Medical University, 100053 Beijing, China.
Neurosci Lett. 2015 Jul 10;599:115-9. doi: 10.1016/j.neulet.2015.05.030. Epub 2015 May 18.
Parkinson's disease (PD) is a neurodegenerative disorder characterized by intracellular α-synuclein (α-syn) deposition. Alterations in α-syn levels in cerebrospinal fluid (CSF) and plasma of PD patients have been thought to be potential PD biomarkers; however, contamination arising from hemolysis often influences the accuracy of detecting α-syn levels in the CSF and plasma. In this study, α-syn oligomer levels in red blood cells (RBCs) obtained from 100 PD patients, 22 MSA patients, and 102 control subjects were measured by enzyme-linked immunosorbent assay. We showed that the ratio of α-syn oligomer/total RBC protein was higher in PD patients than in controls (29.0±19.8 ng/mg vs. 15.4±7.4 ng/mg, P<0.001). The area under the receiver operating characteristic curve (AUC) indicated a sensitivity of 79.0%, specificity of 64.7% and a positive predictive value of 68.7%, with an AUC of 0.76 for increased α-syn oligomer/total RBC protein ratio. However, there was no correlation between RBC α-syn oligomer levels and age at onset, disease duration, age, UPDRS motor scale score or progression of motor degeneration in PD patients. The ratio of RBC α-syn oligomer/total protein was also higher in MSA patients than in controls (22.9±13.9 ng/mg vs. 15.4±7.4 ng/mg, P<0.001). However, no significant difference was found for α-syn oligomer/total protein ratio between PD and MSA (29.0±19.8 ng/mg vs. 22.9±13.9 ng/mg, P>0.05). The present results suggest that the RBC α-syn oligomer/total protein ratio can be a potential diagnostic biomarker for PD.
帕金森病（PD）是一种以细胞内α-突触核蛋白（α-syn）沉积为特征的神经退行性疾病。人们认为，帕金森病患者脑脊液（CSF）和血浆中α-syn水平的改变可能是潜在的帕金森病生物标志物；然而，溶血引起的污染常常影响脑脊液和血浆中α-syn水平检测的准确性。在本研究中，通过酶联免疫吸附测定法测量了100例帕金森病患者、22例多系统萎缩（MSA）患者和102例对照者红细胞（RBC）中的α-syn寡聚体水平。我们发现，帕金森病患者的α-syn寡聚体/总红细胞蛋白比值高于对照组（29.0±19.8 ng/mg对15.4±7.4 ng/mg，P<0.001）。受试者工作特征曲线（AUC）下的面积显示，α-syn寡聚体/总红细胞蛋白比值升高时，敏感性为79.0%，特异性为64.7%，阳性预测值为68.7%，AUC为0.76。然而，帕金森病患者红细胞α-syn寡聚体水平与发病年龄、病程、年龄、统一帕金森病评定量表（UPDRS）运动量表评分或运动功能退化进展之间无相关性。多系统萎缩患者的红细胞α-syn寡聚体/总蛋白比值也高于对照组（22.9±13.9 ng/mg对15.4±7.4 ng/mg，P<0.001）。然而，帕金森病和多系统萎缩患者之间的α-syn寡聚体/总蛋白比值无显著差异（29.0±19.8 ng/mg对22.9±13.9 ng/mg，P>0.05）。目前的结果表明，红细胞α-syn寡聚体/总蛋白比值可能是帕金森病的一种潜在诊断生物标志物。
